Insider Selling: Insulet Co. (PODD) EVP Sells 7,250 Shares of Stock

Insulet Co. (NASDAQ:PODD) EVP Bradley A. Thomas sold 7,250 shares of the firm’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $83.81, for a total transaction of $607,622.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of Insulet Co. (NASDAQ:PODD) traded up $0.62 during trading hours on Friday, hitting $85.23. 511,279 shares of the stock traded hands, compared to its average volume of 474,056. The firm has a market cap of $4,940.47, a PE ratio of -185.28 and a beta of 1.56. The company has a quick ratio of 5.85, a current ratio of 6.24 and a debt-to-equity ratio of 3.57. Insulet Co. has a one year low of $38.43 and a one year high of $85.71.

How to Become a New Pot Stock Millionaire

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The firm had revenue of $130.50 million during the quarter, compared to analyst estimates of $125.16 million. Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. Insulet’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. sell-side analysts forecast that Insulet Co. will post -0.3 EPS for the current fiscal year.

A number of analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Insulet from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research note on Friday, March 9th. BMO Capital Markets initiated coverage on shares of Insulet in a research note on Monday, March 5th. They set an “outperform” rating and a $90.00 target price for the company. Jefferies Group reiterated a “buy” rating and issued a $90.00 price objective on shares of Insulet in a research note on Friday, February 23rd. Finally, Canaccord Genuity lifted their price objective on shares of Insulet from $78.00 to $88.00 and gave the stock a “neutral” rating in a research note on Friday, February 23rd. Eight equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $73.24.

Several large investors have recently modified their holdings of PODD. First Trust Advisors LP raised its position in shares of Insulet by 96.6% in the 3rd quarter. First Trust Advisors LP now owns 33,473 shares of the medical instruments supplier’s stock valued at $1,844,000 after buying an additional 16,444 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Insulet by 14.0% in the 3rd quarter. New York State Common Retirement Fund now owns 71,585 shares of the medical instruments supplier’s stock valued at $3,943,000 after buying an additional 8,785 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Insulet by 6.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 289,027 shares of the medical instruments supplier’s stock valued at $15,919,000 after buying an additional 18,111 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Insulet by 3.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 30,200 shares of the medical instruments supplier’s stock valued at $1,662,000 after buying an additional 1,146 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Insulet by 163.5% in the 3rd quarter. SG Americas Securities LLC now owns 9,247 shares of the medical instruments supplier’s stock valued at $509,000 after buying an additional 5,738 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Insulet Co. (PODD) EVP Sells 7,250 Shares of Stock” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.chaffeybreeze.com/2018/03/17/insider-selling-insulet-co-podd-evp-sells-7250-shares-of-stock.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply